These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


387 related items for PubMed ID: 10824027

  • 1. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L, Moore T, Niconovich N, Donald B, Broskey J, Jakielaszek C, Rittenhouse S, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Apr; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci.
    Ieven M, Goossens W, De Wit S, Goossens H.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():51-3. PubMed ID: 10824033
    [Abstract] [Full Text] [Related]

  • 4. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
    Gönüllü N, Aktaş Z, Salcioglu M, Bal C, Ang O.
    Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J, St-Pierre C.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
    Yong DE, Cheong HJ, Kim YS, Park YJ, Kim WJ, Woo JH, Lee KW, Kang MW, Choo YS.
    J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H, Stepanik D, Vilches V, Scarano S, Sarachian B, Mikaelian G, Finlay J, Sucari A.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [Abstract] [Full Text] [Related]

  • 10. Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
    Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354
    [Abstract] [Full Text] [Related]

  • 11. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 12. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro.
    Higgins PG, Coleman K, Amyes SG.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():71-7. PubMed ID: 10824036
    [Abstract] [Full Text] [Related]

  • 13. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S, McCloskey L, Broskey J, Niconovich N, Jakielaszek C, Poupard J, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of gemifloxacin.
    King A, May J, French G, Phillips I.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [Abstract] [Full Text] [Related]

  • 15. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 16. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F, Cercenado E, Martín-Pedroviejo J, Cuevas O, Bouza E.
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR.
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [Abstract] [Full Text] [Related]

  • 18. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
    Dembry LM, Roberts JC, Schock KD, Marino SP, Farrel PA, Andriole VT.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
    [Abstract] [Full Text] [Related]

  • 19. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
    Wise R, Andrews JM.
    J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 20.